Natera is a global company in cell-free DNA (cfDNA) testing, developing genetic diagnostics intended to support earlier detection and more personalized care. Its work spans prenatal screening, molecular oncology and transplant monitoring, and it reports detection sensitivity down to a single molecule in a tube of blood. The company operates from sites in Austin, Texas and San Carlos, California, and serves patients and healthcare providers worldwide.
Three tests form the core of its product portfolio. Panorama is a prenatal screening test based on cell-free DNA. Signatera is a personalized cancer detection test used for molecular residual disease monitoring. Prospera applies cell-free DNA to transplant monitoring. The underlying technical fields include molecular biology, bioinformatics software, artificial intelligence and single-molecule detection.
Natera states that more than 300 peer-reviewed publications support its technology. Its laboratories are ISO 13485-certified, CAP-accredited and CLIA-certified. The company describes a mission-driven focus on making personalized genetic testing part of the standard of care, with an emphasis on innovation, earlier detection and targeted interventions.
